OsteoCure Therapeutics

OsteoCure Therapeutics, a Duke University spinout and Johnson & Johnson JLABS company based in Durham, North Carolina, is developing OCTA1, a first-in-class injectable therapy designed to accelerate bone healing while simultaneously reducing pain. OCTA1 is a device led combination product that is composed of a hyaluronic acid scaffold with sustained-release microgels that deliver adenosine, a naturally occurring molecule critical for bone regeneration and pain modulation. Preclinical studies have demonstrated significant improvements in fracture healing and functional recovery, with strong statistical significance in both bone repair and analgesia. For civilian medicine, OCTA1 offers a minimally invasive, opioid-sparing solution for treating fusions, fractures, and other orthopedic trauma, enabling faster recovery for patients from athletes to older adults. In military medicine, the technology addresses critical needs in combat casualty care and training-related musculoskeletal injuries such as stress fractures, by providing a deployable, shelf-stable, and rapidly administered intervention that improves healing outcomes and reduces downtime, ultimately enhancing force readiness while also benefiting the long-term musculoskeletal health of veterans